ConvaTec Group PLC
CTEC
Company Profile
Business description
Originally spun out of Bristol-Myers Squibb, ConvaTec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
Contact
20 Eastbourne Terrace
7th Floor
Paddington
LondonW2 6LG
GBRT: +44 7826447807
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
10,000
Stocks News & Analysis
stocks
Fair value downgraded for ASX heavyweight
Our capital allocation rating was also lowered due to balance sheet weakness.
stocks
ChatGPT enters the retail space and one company surges
Investors cheer the ability to purchase directly from ChatGPT.
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,122.00 | 0.50 | 0.01% |
| CAC 40 | 7,895.94 | 15.07 | 0.19% |
| DAX 40 | 23,880.72 | 135.66 | 0.57% |
| Dow JONES (US) | 46,397.89 | 81.82 | 0.18% |
| FTSE 100 | 9,350.43 | 50.59 | 0.54% |
| HKSE | 26,855.56 | 232.68 | 0.87% |
| NASDAQ | 22,660.01 | 68.86 | 0.30% |
| Nikkei 225 | 44,544.19 | 388.44 | -0.86% |
| NZX 50 Index | 13,433.99 | 141.63 | 1.07% |
| S&P 500 | 6,688.46 | 27.25 | 0.41% |
| S&P/ASX 200 | 8,831.20 | 2.20 | -0.02% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |